Time: July 27-28, 2019 (registered all day on July 26)
Venue: Four Points Hotel, Suzhou (8 Moonwan Road, Dushu Lake Higher Education District, Suzhou Industrial Park)
The development of the international biopharmaceutical industry has been remarkable in the past year. New technologies, new products and new solutions are emerging, especially for tumor immunity and cellular immunotherapy. Domestic biopharmaceuticals are on the rise, especially antibody drugs, and many companies' innovative drugs are entering the clinical stage. With the rapid launch of the first domestic PD-1 antibody and biosimilar drugs, China's biopharmaceuticals entered a new era. Product marketization, competition for similar products, and medical insurance access pricing reimbursement continue to be hot news. Along with the dramatic changes in the international trade situation, industrial sustainable development has suddenly become a problem that must be faced. Therefore, while embracing the changes, we should be more prepared to deal with the challenges.
The China Protein Drug Quality Alliance is a non-profit product quality self-discipline and industrial technology innovation professional group composed of voluntary enterprises and academic research institutions engaged in the protein and pharmaceutical industry. Its member units include more than 50 leading biopharmaceutical companies and academic research institutions in China, such as Diane Ji Shi, Jiahe Bio, Fuhong Hanlin, Sansheng Guojian and Hisun Pharmaceutical. Since its establishment, it has successfully held more than ten seminars on quality and technology innovation of protein drugs, and has gradually become a platform for the exchange of protein medicine/biopharmaceutical academic industry with extensive influence in China.
2019 China Biopharmaceutical Quality and Technology Innovation Seminar (BioMed China 2019) will be held in China's biomedical industry highland, Suzhou Industrial Park. Top experts from relevant regulatory departments, biotechnology, biopharmaceutical companies, medical institutions and research institutes will explore new biotech technologies and products in response to new challenges such as post-marketing challenges, new policies for medical insurance and drastic changes in foreign trade. Key issues such as production process improvement, analytical quality control, and industrial sustainability.
Contact Person: Mr. zhao